Year-end Sale % OFF 
Abstract
The standard treatment for patients with good performance status with unresectable LANSCLC is concurrent chemoradiotherapy (CRT), The new treatment strategies of patients who could not tolerate CRT or refused chemotherapy are necessary. Anlotinib is a novel multi-target antiangiogenesis agent that inhibits VEGFR, FGFR, PDGFR, c-kit, which showed encouraging efficacy and good tolerability for advanced NSCLC in ALTER-0303 trial. Emerging clinical data suggested that antiangiogenic drugs could enhance the efficacy of radiotherapy by alleviating tumor hypoxia and improving perfusion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
